The UK and US have agreed to a key trade agreement that will keep zero duties on British medicine products being sold in the American market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has pledged to increase funding on medicines through the public health system. This commitment guarantees that import taxes on these vital exports will remain at nothing for a timeframe of the next three years.
This agreement follows previous threats to significantly raise duties on branded pharmaceutical imports, with potential rates floated up to double the cost.
"This deal with the UK bolsters the international landscape for innovative medicines and brings long-overdue fairness to transatlantic medicine commerce," an announcement declared.
Trade Significance
Drugs represent one of the the United Kingdom's biggest export categories to the United States, which is easily the largest buyer for major British pharmaceutical firms.
Trade data reveal that in the 12 months to the end of last September, the UK shipped drugs worth £11.1bn to the US. This value made up nearly one-fifth of all goods exports in that span.
"This agreement secures work, increases investment and sets the stage for the UK to become a international leader for life sciences," a government official stated.
Detailed NHS Changes
The deal involves several key commitments from the British government:
- Revised Affordability Limit: The UK will lift the price threshold at which it judges new medicines to be unaffordable by 25%.
- Boosted Medicine Funding: There is a goal to raise total public funding on medicines from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Rebate Cap: The sum manufacturers must refund to the NHS to prevent overspending will be restricted at fifteen percent. Last year, rebates were more than 20%.
Broader Context
The deal comes amid a protracted row between the pharmaceutical industry and the ministers over medicine costs and approval rates.
This friction were intensified by arguments that American consumers were paying several times more for the same drugs than consumers in the Britain and the EU.
Over the last 18 months, several large pharmaceutical investments in the UK have been delayed or scrapped, while major expansions have been pledged toward US facilities.
A senior figure publicly accepted that the NHS must invest a greater share on treatments, noting that its expenditure on drugs had decreased as a proportion of its overall budget over the past decade.
